Antineoplastics Reactions 1680, p39 - 2 Dec 2017 Atypia: 5 case reports In a retrospective study, five women, aged 29 52 years, were described who developed cervical atypia during treatment with cyclophosphamide and busulfan (two women), fludarabine, busulfan and cyclophosphamide (two women) and fludarabine, cytarabine, busulfan and cyclophosphamide (one woman) [not all dosages and routes stated]. Additionally, all the women received mesna. The women underwent haematopoietic stem cell transplantation (HSCT). They received myeloablative conditioning (MAC) therapy (two women) and reduced intensity-conditioning (RIC) therapy (three women). The MAC therapy was consisted of IV busulfan 3.2 mg/kg/day for four days and cyclophosphamide 60 mg/kg/day for two days. The RIC was consisted of IV busulfan 3.2 mg/kg/day for two days, fludarabine 30 mg/m /day for five days and cyclophosphamide 50 mg/kg/day for one day in two women and in the remaining woman, the RIC was consisted of fludarabine, cytarabine, busulfan and cyclophosphamide. All the women received prophylactic mesna. After 34-183 days of HSCT, all the women developed therapy-related atypia. One out of these five women underwent cervical biopsy, which suggestive of therapy-related atypia. A pap smears tests findings were consistent with the diagnosis of atypical squamous cells of undetermined significance (ASC-US) in two women. The therapy-related atypia was transient in nature. Twenty to twenty nine months after HSCT, the pap smears tests showed no atypia in three women. Author comment: "In summary, therapy-related atypia is extremely common during the acute phase after HSCT. The atypical cytology is probably associated with conditioning chemotherapy, particularly busulfan-containing regimens." Yu S-C, et al. Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase. Biology of Blood and Marrow Transplantation 23: 1367-1373, No. 8, Aug 2017. Available from: URL: - Taiwan 803285536 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial